Other languages Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
8.29 ^USD	+0.48%		-6.43%	-22.70%

Apr. 18	Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
Apr. 15	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Apr. 18
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	Feb. 01
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	Jan. 08
Traders Look Ahead to Flat Day After Post-Christmas Rally	Dec. 27
Top Premarket Decliners	Dec. 27
Sector Update: Health Care Stocks Stronger Late Afternoon	Dec. 26
Sector Update: Health Care Stocks Steady Tuesday Afternoon	Dec. 26
Oncternal Therapeutics Says One Patient Dies in Dose Expansion Phase 1/2 Trial of ONCT-808 for B-cell Lymphoma; Shares Fall	Dec. 26
Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	Dec. 26
Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer	23-10-26
Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board	23-10-25
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer	23-10-05
Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
Oncternal Therapeutics Says US FDA Greenlights Phase 1/2 Trial of Prostate Cancer Drug Candidate	23-08-04
Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma	23-06-06
Oncternal Therapeutics, Inc. Announces Resignation of Gunnar Kaufmann as Chief Scientific Officer, Effective June 14, 2023	23-06-02
Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Other languages

Filters